Yuhui Huang

8PUBLICATIONS
19CO-AUTHORS
Molecular targetsPredictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 04, 2025
High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers.

Peng Fan, Ziwei Qi, Zhenhua Liu

|Jan 31, 2025
Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer.

Zhenhua Liu, Ke Ma, Qingzhu Jia

|Oct 26, 2023
Alleviating hypoxia to improve cancer immunotherapy.

Peng Fan, Naidong Zhang, Eleonora Candi

|Mar 27, 2023
Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy.

Yan Zhang, Jiayan Gao, Yan He

|Oct 28, 2021
The role of DLL1 in long-term vascular normalization and cancer immunotherapy.

Qiaozhen Wu, Yuhui Huang

|May 26, 2021
DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression.

Naidong Zhang, Rongping Yin, Pei Zhou

Pageof 2

Frequent Collaborators

2 joint publications

Eleonora Candi

1 joint publications

Joao Incio

1 joint publications

Keehoon Jung

1 joint publications

Kosuke Kawaguchi